4
Changes in Ownership
Beam Therapeutics Inc. Filed Acc 0001193125-26-138348
CEO sold 50,000 shares at an average $22.57 ($1,128,315)
- CEO acquired 50,000 shares (option exercise)
- CEO acquired 90,000 shares (grant or award)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Evans John M. CEO | 2026-03-30 | Option exercise 10b5-1 | +25,000 | $0.67 | $16,750 | 1,011,667 | D: show line 1 in the form |
| Evans John M. CEO | 2026-03-30 | Sale 10b5-1 | −25,000 | $22.37 | $559,230 | 986,667 | D: show line 2 in the form |
| Evans John M. CEO | 2026-03-31 | Option exercise 10b5-1 | +25,000 | $0.67 | $16,750 | 1,011,667 | D: show line 3 in the form |
| Evans John M. CEO | 2026-03-31 | Sale 10b5-1 | −25,000 | $22.76 | $569,085 | 986,667 | D: show line 4 in the form |
| Evans John M. CEO | 2026-03-31 | Grant or award 10b5-1 | +90,000 | 1,076,667 | D: show line 5 in the form | ||
| Open-market sales · 50,000 sh · avg $22.57 · $1,128,315 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Evans John M. CEO | 2026-03-30 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −25,000 | 43,672 | D: show line 6 in the form | ||
| Evans John M. CEO | 2026-03-31 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −25,000 | 18,672 | D: show line 7 in the form |
Loading xslF345X06/ownership.xml…